Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
Amy S. Paller(Northwestern University), Brad Shumel(Regeneron (United States)), Melinda Gooderham(Queen's University), Jamie Weisman(Institute for Advanced Medical Research), John T. O’Malley(Brigham and Women's Hospital), Michael J. Cork(Royal Hallamshire Hospital), David M. Weinreich(Regeneron (United States)), Peter D. Arkwright(University of Manchester), Bethany Beazley(Regeneron (United States)), Megan Hardin(Sanofi (United States)), Mark Boguniewicz(University of Colorado Denver), Andreas Wollenberg(University Hospital Augsburg), Mohamed Kamal(Regeneron (United States)), Neil M.H. Graham(UK Dementia Research Institute), Lisa A. Beck(Newcastle University), George D. Yancopoulos(Regeneron (United States)), Ashish Bansal(Regeneron (United States)), Diamant Thaçi(University of Lübeck), Elaine C. Siegfried(Saint Louis University), Lawrence Sher(Peninsula Research), Xian Sun(Regeneron (United States)), Marcella Ruddy(Regeneron (United States)), John D. Davis(Providence College), Faisal A. Khokhar(Regeneron (United States)), Naimish Patel(Sanofi (United States))
Cited by 385
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k
Regulation of the Germinal Center Response by MicroRNA-155
|Science|2007|1.5k